Several relevant phase II/III clinical studies (ClinicalTrials.gov Identifiers: NCT05306041, NCT05646862, NCT04191499, and NCT05894239) have been conducted in metastatic and advanced BC patients with PIK3CA mutations and HR-positive or HER2-positive phenotypes, but have not been studied in TNBC. Here, PIK3CA is linked to breast cancer.